Comparative Risk of Suicide-Related Events Across Antidepressant Classes in Autistic Individuals: A New-User Active Comparator Cohort Study
En palabras de los autores
Abstract Introduction: Comparative evidence on suicide-related outcomes across antidepressant treatments among autistic individuals is limited. We examined associations between antidepressant treatment class and suicide-related events (SREs) among individuals on the autism spectrum initiating antidepressants. Methods: We conducted a retrospective new-user, active-comparator cohort study using the nationwide Truveta database of electronic health records. Autistic individuals initiating antidepressants after an autism spectrum diagnosis were classified by initial treatment as a selective serotonin reuptake inhibitor (SSRI), atypical antidepressant, serotonin-norepinephrine reuptake inhibitor (SNRI), or tricyclic antidepressant (TCA). Pairwise propensity score overlap weighting was used to balance baseline characteristics, and associations with SREs during as-treated follow-up were estimated using weighted Cox proportional hazards models. Results: Among 42,441 autistic antidepressant initiators , atypical antidepressants (hazard ratio [HR], 0.787; 95% confidence interval [CI], 0.632-0.979) and TCAs (HR, 0.487; 95% CI, 0.263-0.902) were associated with lower observed SRE hazards compared with SSRIs, whereas no clear difference was observed for SNRIs (HR, 0.948; 95% CI, 0.651-1.381). In agent-specific analyses, trazodone was associated with a lower observed SRE hazard compared with SSRIs, whereas no clear differences were observed for bupropion or mirtazapine. Exploratory age-stratified analyses suggested a lower hazard for atypical antidepressants versus SSRIs among individuals younger than 18 years, although evidence of effect modification was not consistent across alternative specifications of age. Discussion: Among autistic individuals initiating antidepressants, observed SRE hazards differed across some antidepressant treatment comparisons. The class-level association for atypical antidepressants was not observed consistently across its individual agents, and age-related differences warrant further investigation.
Apareció: sábado, 24 de octubre. medRxiv. Preprint, todavía sin revisión por pares.